Advertisement
GMAB vs PCVX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Hold and PCVX is a Hold.
GMAB saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GMAB moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In 41 of the 57 cases the stock moved lower. This puts the odds of a downward move at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GMAB moved out of overbought territory on October 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 24 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
GMAB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on GMAB as a result. In 49 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 05, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 27 of 45 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 196 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 144 of 210 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.650) is normal, around the industry mean (26.782). P/E Ratio (27.949) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PCVX's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 31 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 64 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on PCVX as a result. In 60 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for PCVX just turned positive on October 05, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
PCVX moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 68%.
Following a +31.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 224 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.144) is normal, around the industry mean (26.782). P/E Ratio (12.594) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GMAB | PCVX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 70 | |
SMR RATING 1..100 | 59 | 96 | |
PRICE GROWTH RATING 1..100 | 38 | 37 | |
P/E GROWTH RATING 1..100 | 8 | 35 | |
SEASONALITY SCORE 1..100 | 41 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCVX's Valuation (67) in the null industry is in the same range as GMAB (85). This means that PCVX’s stock grew similarly to GMAB’s over the last 12 months.
PCVX's Profit vs Risk Rating (70) in the null industry is in the same range as GMAB (100). This means that PCVX’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's SMR Rating (59) in the null industry is somewhat better than the same rating for PCVX (96). This means that GMAB’s stock grew somewhat faster than PCVX’s over the last 12 months.
PCVX's Price Growth Rating (37) in the null industry is in the same range as GMAB (38). This means that PCVX’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's P/E Growth Rating (8) in the null industry is in the same range as PCVX (35). This means that GMAB’s stock grew similarly to PCVX’s over the last 12 months.
| GMAB | PCVX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 77% |
| Advances ODDS (%) | 3 days ago 63% | 10 days ago 79% |
| Declines ODDS (%) | 7 days ago 71% | 2 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMAB’s FA Score shows that 1 FA rating(s) are green while PCVX’s FA Score has 0 green FA rating(s).
- GMAB’s FA Score: 1 green, 4 red.
- PCVX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMAB’s TA Score shows that 4 TA indicator(s) are bullish while PCVX’s TA Score has 6 bullish TA indicator(s).
- GMAB’s TA Score: 4 bullish, 4 bearish.
- PCVX’s TA Score: 6 bullish, 4 bearish.
Price Growth
GMAB (@Biotechnology) experienced а -3.25% price change this week, while PCVX (@Biotechnology) price change was +0.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.
Reported Earning Dates
GMAB is expected to report earnings on Nov 05, 2026.
PCVX is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-7.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBDZ | 24.71 | 0.03 | +0.12% |
| iShares iBonds Dec 2034 Term Corporate ETF (IBDZ) | |||
| BMAY | 49.16 | N/A | N/A |
| Innovator U.S. Equity Buffer ETF - May (BMAY) | |||
| USHY | 35.66 | -0.07 | -0.20% |
| iShares Broad USD High Yield Corporate Bond ETF (USHY) | |||
| FIGG | 16.39 | -0.15 | -0.91% |
| Leverage Shares 2x Long FIG Daily ETF (FIGG) | |||
| CCIF | 2.22 | -0.06 | -2.63% |
| Carlyle Credit Income Fund | |||
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | -2.14% | ||
| AXON - GMAB | 47% Loosely correlated | -0.26% | ||
| PCVX - GMAB | 41% Loosely correlated | -5.45% | ||
| RYTM - GMAB | 40% Loosely correlated | -3.57% | ||
| EXEL - GMAB | 39% Loosely correlated | -0.52% | ||
| LKFT - GMAB | 38% Loosely correlated | -1.76% | ||
More | ||||